Share ownership Virax Biolabs Group Limited

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 06/03/2026 GMT			5-day change	1st Jan Change
0.2145 ^USD	+3.62%		-5.80%	-37.97%

12-02	Virax Biolabs Group Limited announced that it expects to receive $5 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI

Share class: Virax Biolabs Group Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,341,956	4,053,969 ( 93.37 %)	0	93.37 %

Major shareholders: Virax Biolabs Group Limited

Name	Equities	%	Valuation
Armistice Capital LLC 11.1 %	823,909	11.1 %	233 166 $
James Foster 4.965 %	368,570	4.965 %	104 305 $
Nigel McCracken 0.3143 %	23,332	0.3143 %	6 603 $
XTX Topco Ltd. 0.2888 %	21,437	0.2888 %	6 067 $
Nelson Haight 0.2065 %	15,333	0.2065 %	4 339 $
Evan Norton 0.2065 %	15,333	0.2065 %	4 339 $
Yair Erez 0.2065 %	15,333	0.2065 %	4 339 $
UBS Securities LLC 0.0988 %	7,332	0.0988 %	2 075 $
National Bank Financial, Inc. 0.0808 %	6,000	0.0808 %	1 698 $
UBS Group AG (13f Subfiler) 0.002155 %	160	0.002155 %	45 $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	11.28%
Individuals	5.9%
Other	0.29%
Unknown	82.53%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	11.2%
Individuals	5.9%
Cayman Islands	0.29%
Canada	0.08%

Based on 1000 largest holdings

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Employees

Sector

Biotechnology & Medical Research

More about the company